More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.84B
EPS
1.52
P/E ratio
141.5
Price to sales
14.94
Dividend yield
--
Beta
0.887698
Previous close
$63.88
Today's open
$62.18
Day's range
$62.00 - $64.57
52 week range
$14.27 - $70.64
show more
CEO
Sean E. Brynjelsen
Employees
44
Headquarters
Deer Park, IL
Exchange
NASDAQ Global Market
Shares outstanding
28842215
Issue type
Common Stock
Healthcare
Pharmaceuticals
Explosive Growth Ignites This Biotech. But There's A Catch.
Robust growth fuels biotech firm Eton Pharmaceuticals, but bearish market conditions have Eton stock facing key test.
Investors Business Daily • 8 hours ago

Eton Pharmaceuticals: The Commercial Model Is Finally Scaling
Eton Pharmaceuticals earns a Buy rating as scalable commercial operations, expanding margins and pipeline launches support continued growth. Third-quarter revenue rose 158% to $57.9 million, with a 49% adjusted EBITDA margin; 2026 revenue guidance increased to more than $175 million. LIBERVANT and ASN-001 are the main growth drivers, with potential launches in 2027 and 2028, respectively.
Seeking Alpha • Nov 16, 2026

Eton Pharmaceuticals Q3 Earnings Call Highlights
Eton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth across its product portfolio.
MarketBeat • Nov 6, 2026

Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion
ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.
Zacks Investment Research • Nov 6, 2026

Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully diluted EPS of $0.50; EBITDA of $24.8 million, Adjusted EBITDA of $28.5 million or 49% of revenue Raised 2026 revenue guidance to more than $175 million, up from prior guidance of more than $145 million; raised 2026 Adjusted EBITDA to more than 40%, up from prior guidance of more than 35% Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2026.
GlobeNewsWire • Nov 5, 2026

Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.07 per share a year ago.
Zacks Investment Research • Nov 6, 2026

Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN ® participants Hepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11% increase with placebo Company plans additional study arms in 2027 evaluating faster-release formulations to seek to improve copper absorption inhibition while preserving favorable safety profile DEER PARK, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced preliminary results from a randomized, double-blind, placebo-controlled pilot study evaluating ET-700, its investigational extended-release zinc acetate formulation being developed to treat Wilson disease.
GlobeNewsWire • Nov 5, 2026

Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will present at the 2026 Jefferies Global Healthcare Conference in London from November 16-19, 2026 as follows:
GlobeNewsWire • Nov 4, 2026

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved Commercial preparations remain on track to support a potential U.S. launch of Anaphylm following FDA approval Ex-U.S. Anaphylm strategy progressing, with Health Canada submission expected in Q4 2026 and an EU filing planned for Q1 2027 Company to host investor call on November 4, 2026, at 8:00 a.m. ET WARREN, N.J.
GlobeNewsWire • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Eton Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.